Objective: To evaluate the clinical benefit of a 3-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients scheduled for palliative treatment. Methods: Eligibility criteria were 2 or more prior chemotherapy regimens, Eastern Cooperative Oncology Group performance status of 2 or less; adequate organ function, assessable disease by serum CA-125 measurement before each cycle; and 1 or more cycle of topotecan (1.5 mg/m2 per day) on 3 consecutive days of a 28-day treatment cycle. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria version 3. Tumor response, stable disease, and progression were evaluated on the basis of CA-125 levels. Results: A total of 68 patients were considered eligible for the study. Median age was 58 years (range, 40-77 years), and the median number of prior chemotherapy regimens was 2 (range, 2-6). A total of 272 cycles of topotecan were administered, with a median of 4 cycles per patient (range, 1-8). No treatment delays or dose reduction was recorded. Major toxicities were grade 3/4 (18%) neutropenia, neutropenic fever (6%), grade 4 thrombocytopenia (3%), requirements for blood (5%), and platelet transfusions (3%). Thirty-five (54%) of the 64 evaluable patients showed a clinical benefit. Of these, 11 patients (17%) had a partial response, and 24 (37%) had stable disease with a median time to progression of 7.5 months (range, 6-10 months) and 4 months (range, 2-6 months), respectively. Conclusion: More than half of heavily pretreated ovarian cancer patients may benefit from 3-day topotecan.

Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients / Calcagno, Marco; Bellati, Filippo; Palaia, Innocenza; Francesco, Plotti; Basile, Stefano; Pastore, Maria; Sansone, Milena; Cristiana, Arrivi; Roberto, Angioli; BENEDETTI PANICI, Pierluigi. - In: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. - ISSN 1048-891X. - 19:3(2009), pp. 455-459. [10.1111/igc.0b013e3181a1a7d2]

Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients

CALCAGNO, MARCO;BELLATI, FILIPPO;PALAIA, INNOCENZA;BASILE, STEFANO;PASTORE, MARIA;SANSONE, MILENA;BENEDETTI PANICI, PIERLUIGI
2009

Abstract

Objective: To evaluate the clinical benefit of a 3-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients scheduled for palliative treatment. Methods: Eligibility criteria were 2 or more prior chemotherapy regimens, Eastern Cooperative Oncology Group performance status of 2 or less; adequate organ function, assessable disease by serum CA-125 measurement before each cycle; and 1 or more cycle of topotecan (1.5 mg/m2 per day) on 3 consecutive days of a 28-day treatment cycle. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria version 3. Tumor response, stable disease, and progression were evaluated on the basis of CA-125 levels. Results: A total of 68 patients were considered eligible for the study. Median age was 58 years (range, 40-77 years), and the median number of prior chemotherapy regimens was 2 (range, 2-6). A total of 272 cycles of topotecan were administered, with a median of 4 cycles per patient (range, 1-8). No treatment delays or dose reduction was recorded. Major toxicities were grade 3/4 (18%) neutropenia, neutropenic fever (6%), grade 4 thrombocytopenia (3%), requirements for blood (5%), and platelet transfusions (3%). Thirty-five (54%) of the 64 evaluable patients showed a clinical benefit. Of these, 11 patients (17%) had a partial response, and 24 (37%) had stable disease with a median time to progression of 7.5 months (range, 6-10 months) and 4 months (range, 2-6 months), respectively. Conclusion: More than half of heavily pretreated ovarian cancer patients may benefit from 3-day topotecan.
2009
3-day schedule; recurrent ovarian cancer; salvage chemotherapy; topotecan
01 Pubblicazione su rivista::01a Articolo in rivista
Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients / Calcagno, Marco; Bellati, Filippo; Palaia, Innocenza; Francesco, Plotti; Basile, Stefano; Pastore, Maria; Sansone, Milena; Cristiana, Arrivi; Roberto, Angioli; BENEDETTI PANICI, Pierluigi. - In: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. - ISSN 1048-891X. - 19:3(2009), pp. 455-459. [10.1111/igc.0b013e3181a1a7d2]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/366712
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact